GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ainos Inc (NAS:AIMD) » Definitions » Sloan Ratio %

Ainos (AIMD) Sloan Ratio % : -32.50% (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Ainos Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Ainos's Sloan Ratio for the quarter that ended in Mar. 2024 was -32.50%.

Warning Sign:

When sloan ratio (-28.18)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Mar. 2024, Ainos has a Sloan Ratio of -32.50%, indicating earnings are more likely to be made up of accruals.


Ainos Sloan Ratio % Historical Data

The historical data trend for Ainos's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ainos Sloan Ratio % Chart

Ainos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -110.39 -363.08 -6.02 -27.85 -28.18

Ainos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.36 -31.01 -17.58 -28.19 -32.50

Competitive Comparison of Ainos's Sloan Ratio %

For the Medical Devices subindustry, Ainos's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ainos's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ainos's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Ainos's Sloan Ratio % falls into.



Ainos Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Ainos's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-13.771--4.695
--0.102)/31.842
=-28.18%

Ainos's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(-14.566--4.757
--0.14)/29.754
=-32.50%

Ainos's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -2.35 (Jun. 2023 ) + -2.976 (Sep. 2023 ) + -5.925 (Dec. 2023 ) + -3.315 (Mar. 2024 ) = $-14.57 Mil.
Ainos's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -1.146 (Jun. 2023 ) + -0.743 (Sep. 2023 ) + -1.373 (Dec. 2023 ) + -1.495 (Mar. 2024 ) = $-4.76 Mil.
Ainos's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 0.001 (Jun. 2023 ) + -0.046 (Sep. 2023 ) + 0.016 (Dec. 2023 ) + -0.111 (Mar. 2024 ) = $-0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ainos  (NAS:AIMD) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Ainos has a Sloan Ratio of -32.50%, indicating earnings are more likely to be made up of accruals.


Ainos Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Ainos's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ainos (AIMD) Business Description

Traded in Other Exchanges
N/A
Address
8880 Rio San Diego Drive, Suite 800, San Diego, CA, USA, 92108
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low dose oral form.
Executives
Meng Lin Sung officer: Chief Financial Officer 8880 RIO SAN DIEGO DRIVE, STE 800, SAN DIEGO CA 92108
Ting-chuan Lee director 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Ainos Inc 10 percent owner 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Pao-sheng Wei director 10F NO 180 SECTION 2, JIANGUO N RD, TAIPEI F5 104071
Chun-hsien Tsai director, officer: Chairman, CEO, CFO 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Chung-jung Tsai director 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Yao-chung Chiang director 5F, 7 ALY 69, LANE 161, TUNHUA S RD., SEC 1, TAIPEI F5 10675
Wen-han Chang director NO 463 FL 4, MING-SHUE ROAD, TAIPEI F5 104046
Lawrence K Lin other: EVP - OPERATIONS 2871 NETTLE CREEK COURT, CHULA VISTA CA 92108
Hui-lan Wu officer: Chief Financial Officer 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Hsiu-chen Chiu director 9F-1, NO 22, AIGUO E RD, ZHONGZHENG DIST, TAIPEI F5 100408
Chung-yi Tsai director 105 SEQUOIA CT, LOS GATOS CA 95032
Stephen T Chen director 1 GROVE ST, UNIT 812007, WELLESLEY MA 02482-8201
Bernard H Cohen officer: VP, CFO 4134 BUSINESS PARK DRIVE, AMARILLO TX 79110
Dennis Dean Moore director 402 FISH HATCHERY ROAD, HAMILTON MT 59840